The Cooper Companies stock (US2166481027): earnings momentum in eye care and fertility

The Cooper Companies, a US-based specialist in contact lenses and fertility-focused medical devices, recently reported results for its fiscal second quarter of 2024, underscoring solid demand in both its CooperVision and CooperSurgical segments, according to a company results release dated 05/30/2024 and related coverage by Reuters as of 05/30/2024.CooperCompanies IR as of 05/30/2024 and Reuters as of 05/30/2024.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

The Cooper Companies: core business model

The Cooper Companies operates through two primary segments: CooperVision and CooperSurgical. CooperVision develops, manufactures and markets soft contact lenses for the correction of vision, with a focus on daily disposable and specialty lenses, according to the company’s description in its fiscal 2023 Form 10?K filed with the US Securities and Exchange Commission on 12/21/2023.SEC filing as of 12/21/2023.

CooperSurgical focuses on fertility and women’s health. Its portfolio includes products used in in vitro fertilization (IVF) clinics, such as culture media and laboratory equipment, as well as genetic testing and office and surgical devices aimed at gynecologists and obstetricians, based on the same fiscal 2023 Form 10?K published on 12/21/2023.Company website as of 2024.

From a business model perspective, the company emphasizes recurring revenue streams. In eye care, this mainly comes from replacement of soft contact lenses, with many patients using daily or monthly lenses that need regular replenishment. In fertility and women’s health, laboratories and clinics routinely reorder consumables like media and testing kits, creating repeat demand alongside periodic purchases of capital equipment, according to the fiscal 2023 Form 10?K filed on 12/21/2023.

Geographically, the Cooper Companies generates revenue across North America, Europe and Asia-Pacific. The United States is a key market for both CooperVision and CooperSurgical, and the company has repeatedly highlighted the importance of US demand for premium contact lenses and fertility treatments, based on regional breakdowns and management commentary in the fiscal 2023 Form 10?K dated 12/21/2023 and the Q2 2024 results release on 05/30/2024.

Main revenue and product drivers for The Cooper Companies

In its fiscal second-quarter 2024 results release dated 05/30/2024, the Cooper Companies reported continued growth in its CooperVision segment, driven by strong uptake of daily disposable silicone hydrogel lenses and specialty toric lenses. Management pointed to these premium categories as outgrowing the broader contact lens market, supporting revenue expansion and product mix improvement, according to the 05/30/2024 release and accompanying commentary.CooperCompanies IR as of 05/30/2024.

On the fertility and women’s health side, CooperSurgical reported sustained demand from IVF clinics and diagnostic labs, particularly for consumables and fertility-focused devices. The company emphasized the role of fertility equipment, genetic testing solutions and women’s health products in driving segment revenue, with trends influenced by demographics and increasing utilization of assisted reproductive technologies, according to the same fiscal Q2 2024 communication dated 05/30/2024.

Revenue is also shaped by regional dynamics. In North America, higher adoption of premium daily disposables and advanced fertility services supports average selling prices, while in Europe and Asia-Pacific, the company continues to expand its presence and market share, as discussed in the fiscal 2023 Form 10?K published on 12/21/2023. This geographic diversification helps balance differing regulatory and reimbursement landscapes across the global healthcare market.

For US-focused investors, the combination of recurring revenue streams, exposure to vision correction needs and structural growth in fertility treatment usage can be an important consideration. The contact lens business is closely linked to eye care demand and optometry channel performance in the United States, while the fertility business is tied to the broader adoption of IVF and related technologies, according to the fiscal 2023 Form 10?K dated 12/21/2023.

Conclusion

The Cooper Companies holds a focused position in the global eye care and fertility markets through its CooperVision and CooperSurgical segments, with a business model centered on recurring sales of consumables and premium products, according to its fiscal 2023 Form 10?K dated 12/21/2023 and fiscal second-quarter 2024 results release on 05/30/2024. Recent reporting highlights ongoing growth in high-value contact lenses and sustained demand for fertility-related equipment and supplies, though performance can vary between segments and regions. For US investors, the stock provides exposure to structural trends in vision correction and fertility treatment utilization, balanced against factors such as competition, regulatory frameworks and execution on product innovation and geographic expansion.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.